EP0927194A2 - Neues mitglied der multi-tumor abweichendev wachstumsgene familie - Google Patents

Neues mitglied der multi-tumor abweichendev wachstumsgene familie

Info

Publication number: EP0927194A2
Authority: EP; European Patent Office
Prior art keywords: gene; psafp; cells; proliferative capacity; tumors
Prior art date: 1996-04-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP97919321A

Other languages

English (en)

French (fr)

Inventor

Willem Jan Marie Van De Ven

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vlaams Instituut voor Biotechnologie VIB

Original Assignee

Vlaams Instituut voor Biotechnologie VIB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-04

Filing date

1997-04-04

Publication date

1999-07-07

1997-04-04 Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB

1997-04-04 Priority to EP97919321A priority Critical patent/EP0927194A2/de

1999-07-07 Publication of EP0927194A2 publication Critical patent/EP0927194A2/de

Status Withdrawn legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 152
206010028980 Neoplasm Diseases 0.000 title claims abstract description 43
230000001594 aberrant effect Effects 0.000 title claims abstract description 27
230000012010 growth Effects 0.000 title claims abstract description 7
210000000349 chromosome Anatomy 0.000 claims abstract description 47
201000011510 cancer Diseases 0.000 claims abstract description 19
230000001225 therapeutic effect Effects 0.000 claims abstract description 8
210000004027 cell Anatomy 0.000 claims description 46
102000004169 proteins and genes Human genes 0.000 claims description 30
230000005945 translocation Effects 0.000 claims description 28
238000000034 method Methods 0.000 claims description 24
239000000523 sample Substances 0.000 claims description 23
108020004414 DNA Proteins 0.000 claims description 20
230000002062 proliferating effect Effects 0.000 claims description 20
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 19
210000000481 breast Anatomy 0.000 claims description 19
230000004927 fusion Effects 0.000 claims description 19
239000002299 complementary DNA Substances 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
230000004075 alteration Effects 0.000 claims description 14
238000004458 analytical method Methods 0.000 claims description 14
210000004072 lung Anatomy 0.000 claims description 14
239000002773 nucleotide Substances 0.000 claims description 13
125000003729 nucleotide group Chemical group 0.000 claims description 13
238000001574 biopsy Methods 0.000 claims description 12
108020004999 messenger RNA Proteins 0.000 claims description 12
239000012634 fragment Substances 0.000 claims description 11
230000035772 mutation Effects 0.000 claims description 11
238000003757 reverse transcription PCR Methods 0.000 claims description 11
238000003745 diagnosis Methods 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 10
238000006467 substitution reaction Methods 0.000 claims description 10
206010046798 Uterine leiomyoma Diseases 0.000 claims description 9
201000010260 leiomyoma Diseases 0.000 claims description 9
201000007954 uterine fibroid Diseases 0.000 claims description 9
208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 8
238000001514 detection method Methods 0.000 claims description 8
238000002405 diagnostic procedure Methods 0.000 claims description 8
208000008479 Pleomorphic salivary gland adenoma Diseases 0.000 claims description 7
201000009030 Carcinoma Diseases 0.000 claims description 6
208000002927 Hamartoma Diseases 0.000 claims description 6
206010024612 Lipoma Diseases 0.000 claims description 6
238000011065 in-situ storage Methods 0.000 claims description 6
238000013507 mapping Methods 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
108091008146 restriction endonucleases Proteins 0.000 claims description 6
238000000926 separation method Methods 0.000 claims description 6
208000007659 Fibroadenoma Diseases 0.000 claims description 5
206010039491 Sarcoma Diseases 0.000 claims description 5
230000000295 complement effect Effects 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
210000004696 endometrium Anatomy 0.000 claims description 5
229920002521 macromolecule Polymers 0.000 claims description 5
201000008806 mesenchymal cell neoplasm Diseases 0.000 claims description 5
208000009091 myxoma Diseases 0.000 claims description 5
201000008968 osteosarcoma Diseases 0.000 claims description 5
201000009410 rhabdomyosarcoma Diseases 0.000 claims description 5
210000003491 skin Anatomy 0.000 claims description 5
210000001685 thyroid gland Anatomy 0.000 claims description 5
108020005544 Antisense RNA Proteins 0.000 claims description 4
206010066476 Haematological malignancy Diseases 0.000 claims description 4
206010025323 Lymphomas Diseases 0.000 claims description 4
238000002105 Southern blotting Methods 0.000 claims description 4
230000000692 anti-sense effect Effects 0.000 claims description 4
239000003184 complementary RNA Substances 0.000 claims description 4
238000002474 experimental method Methods 0.000 claims description 4
238000009396 hybridization Methods 0.000 claims description 4
208000032839 leukemia Diseases 0.000 claims description 4
208000025443 tumor of adipose tissue Diseases 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 3
238000005516 engineering process Methods 0.000 claims description 3
230000002779 inactivation Effects 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
230000031864 metaphase Effects 0.000 claims description 3
238000001262 western blot Methods 0.000 claims description 3
108090000994 Catalytic RNA Proteins 0.000 claims description 2
102000053642 Catalytic RNA Human genes 0.000 claims description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
230000002950 deficient Effects 0.000 claims description 2
239000003623 enhancer Substances 0.000 claims description 2
230000016507 interphase Effects 0.000 claims description 2
108091092562 ribozyme Proteins 0.000 claims description 2
241000894007 species Species 0.000 claims description 2
238000009007 Diagnostic Kit Methods 0.000 claims 5
238000010171 animal model Methods 0.000 claims 5
239000008194 pharmaceutical composition Substances 0.000 claims 5
241001465754 Metazoa Species 0.000 claims 4
239000013615 primer Substances 0.000 claims 3
150000001875 compounds Chemical class 0.000 claims 2
239000003155 DNA primer Substances 0.000 claims 1
241000124008 Mammalia Species 0.000 claims 1
108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
241000282577 Pan troglodytes Species 0.000 claims 1
241000288906 Primates Species 0.000 claims 1
210000001671 embryonic stem cell Anatomy 0.000 claims 1
230000004077 genetic alteration Effects 0.000 claims 1
230000006801 homologous recombination Effects 0.000 claims 1
238000002744 homologous recombination Methods 0.000 claims 1
239000002751 oligonucleotide probe Substances 0.000 claims 1
108091033319 polynucleotide Proteins 0.000 claims 1
230000009261 transgenic effect Effects 0.000 claims 1
101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 32
102100028999 High mobility group protein HMGI-C Human genes 0.000 description 29
101150035390 mag gene Proteins 0.000 description 12
238000002560 therapeutic procedure Methods 0.000 description 9
230000010261 cell growth Effects 0.000 description 8
108700024394 Exon Proteins 0.000 description 7
230000002559 cytogenic effect Effects 0.000 description 7
208000004333 pleomorphic adenoma Diseases 0.000 description 7
230000003321 amplification Effects 0.000 description 5
238000010804 cDNA synthesis Methods 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
210000004881 tumor cell Anatomy 0.000 description 5
108020004705 Codon Proteins 0.000 description 4
108700039143 HMGA2 Proteins 0.000 description 4
101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 4
238000000636 Northern blotting Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
208000031404 Chromosome Aberrations Diseases 0.000 description 3
206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 3
230000004568 DNA-binding Effects 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
238000013459 approach Methods 0.000 description 3
210000001106 artificial yeast chromosome Anatomy 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
230000002759 chromosomal effect Effects 0.000 description 3
201000000292 clear cell sarcoma Diseases 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical group 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000000306 recurrent effect Effects 0.000 description 3
210000003079 salivary gland Anatomy 0.000 description 3
108091008038 CHOP Proteins 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
102000005720 Glutathione transferase Human genes 0.000 description 2
108010070675 Glutathione transferase Proteins 0.000 description 2
102000049982 HMGA2 Human genes 0.000 description 2
108091027305 Heteroduplex Proteins 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
241001446467 Mama Species 0.000 description 2
WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
208000037062 Polyps Diseases 0.000 description 2
238000010240 RT-PCR analysis Methods 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
201000011143 bone giant cell tumor Diseases 0.000 description 2
208000016160 chondroid hamartoma Diseases 0.000 description 2
231100000005 chromosome aberration Toxicity 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
208000016018 endometrial polyp Diseases 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000010606 normalization Methods 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
206010046811 uterine polyp Diseases 0.000 description 2
SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
102100037674 Bis(5'-adenosyl)-triphosphatase Human genes 0.000 description 1
101150012716 CDK1 gene Proteins 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 1
230000007023 DNA restriction-modification system Effects 0.000 description 1
208000021994 Diffuse astrocytoma Diseases 0.000 description 1
101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
101150099271 FHIT gene Proteins 0.000 description 1
208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
101001027506 Homo sapiens Bis(5'-adenosyl)-triphosphatase Proteins 0.000 description 1
101100502772 Homo sapiens FHIT gene Proteins 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
101710159910 Movement protein Proteins 0.000 description 1
101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010073137 Myxoid liposarcoma Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
102100024147 Protein phosphatase 1 regulatory subunit 14A Human genes 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010051636 Salivary gland adenoma Diseases 0.000 description 1
101100315733 Schizosaccharomyces pombe (strain 972 / ATCC 24843) uap2 gene Proteins 0.000 description 1
206010053871 Trisomy 8 Diseases 0.000 description 1
101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
241001237726 Yoma Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
210000005221 acidic domain Anatomy 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
208000028435 angiomyxoma Diseases 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
208000012080 benign lipomatous neoplasm Diseases 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
208000020719 chondrogenic neoplasm Diseases 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004590 computer program Methods 0.000 description 1
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
238000012303 cytoplasmic staining Methods 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
201000001169 fibrillary astrocytoma Diseases 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000003128 head Anatomy 0.000 description 1
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
238000012758 nuclear staining Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000003681 parotid gland Anatomy 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000011820 transgenic animal model Methods 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
208000034298 trisomy chromosome 8 Diseases 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Definitions

a 1.7 Mb region on chromosome 12 encompasses the chromosome 12 breakpoints of uterine leiomyoma-, lipoma-, and salivary gland adenoma- cells, with the breakpoint cluster regions of the various tumor types overlapping [25] .
MAR Multiple Aberration Region

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Immunology (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

EP97919321A 1996-04-04 1997-04-04 Neues mitglied der multi-tumor abweichendev wachstumsgene familie Withdrawn EP0927194A2 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP97919321A EP0927194A2 (de)	1996-04-04	1997-04-04	Neues mitglied der multi-tumor abweichendev wachstumsgene familie

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP96200966		1996-04-04
EP96200966		1996-04-04
EP97919321A EP0927194A2 (de)	1996-04-04	1997-04-04	Neues mitglied der multi-tumor abweichendev wachstumsgene familie
PCT/EP1997/001710 WO1997038083A2 (en)	1996-04-04	1997-04-04	New member of the multiple-tumor aberrant growth gene family

Publications (1)

Publication Number	Publication Date
EP0927194A2 true EP0927194A2 (de)	1999-07-07

Family

ID=8223856

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP97919321A Withdrawn EP0927194A2 (de)	1996-04-04	1997-04-04	Neues mitglied der multi-tumor abweichendev wachstumsgene familie

Country Status (3)

Country	Link
EP (1)	EP0927194A2 (de)
AU (1)	AU2383897A (de)
WO (1)	WO1997038083A2 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5180819A (en) *	1989-12-22	1993-01-19	The Trustees Of Columbia University In The City Of New York	Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
JPH08510651A (ja) *	1994-03-18	1996-11-12	ミリアド・ジェネティックス・インコーポレイテッド	Ｍｔｓ遺伝子、それにおける変異、およびｍｔｓ遺伝子配列を用いる癌の診断方法

1997
- 1997-04-04 WO PCT/EP1997/001710 patent/WO1997038083A2/en not_active Ceased
- 1997-04-04 AU AU23838/97A patent/AU2383897A/en not_active Abandoned
- 1997-04-04 EP EP97919321A patent/EP0927194A2/de not_active Withdrawn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9738083A3 *

Also Published As

Publication number	Publication date
AU2383897A (en)	1997-10-29
WO1997038083A2 (en)	1997-10-16
WO1997038083A3 (en)	1998-01-22

Legal Events

Date	Code	Title	Description
1999-05-21	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1999-07-07	17P	Request for examination filed	Effective date: 19981104
1999-07-07	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2003-07-16	17Q	First examination report despatched	Effective date: 20030603
2004-03-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2004-04-21	18D	Application deemed to be withdrawn	Effective date: 20031014

Publication	Publication Date	Title
EP1762619B1 (de)	2013-06-26	Multi-tumor abweichende Wachstumsgene
EP0821733B1 (de)	2004-10-20	Genetische marker für brust und eierstockkrebs
US6207374B1 (en)	2001-03-27	Tuberous sclerosis 2 gene and uses thereof
US20040170994A1 (en)	2004-09-02	DNA sequences for human tumour suppressor genes
US20020102245A1 (en)	2002-08-01	14-3-3sigma arrests the cell cycle
EP0837935B1 (de)	2003-08-20	3'utr des menschliches prohibitin-gens
US6207375B1 (en)	2001-03-27	TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
EP1195382B1 (de)	2006-04-12	Testis-spezifisches Gen
US20020009720A1 (en)	2002-01-24	Plag gene family and tumorigenesis
WO1997038083A2 (en)	1997-10-16	New member of the multiple-tumor aberrant growth gene family
JPH07289297A (ja)	1995-11-07	癌抑制遺伝子
AU759752B2 (en)	2003-05-01	Multiple-tumor aberrant growth genes
US7556920B2 (en)	2009-07-07	Gene BNO1 mapping to chromosome 16q24.3
WO1999003883A1 (en)	1999-01-28	Compositions and methods based upon the tuberous sclerosis-1 (tsc1) gene and gene product
AU2007200451A1 (en)	2007-02-22	Multiple-tumor aberrant growth genes
WO2002018592A1 (en)	2002-03-07	Tumour suppressor gene
WO2000015795A2 (en)	2000-03-23	Genes from human chromosome 11p15.5
DE DK et al.	0	NEUES, AUF CHROMOSOM 16Q24. 3 KARTIERTES GEN BNO1 UNE NOUVELLE CARTOGRAPHIE DU GENE BNO1 AU CHROMOSOME 16Q24. 3
WO1998015650A2 (en)	1998-04-16	Hydronephrosis gene (hng) and its use
AU2001287348A1 (en)	2002-03-13	Tumour suppressor gene